Recipharm Expands US Manufacturing Operations with Investment in Biologics and Advanced Therapies

Recipharm, a leading global contract development and manufacturing organisation (CDMO), announced a multi-million-dollar investment in its US operations, strengthening its ability to support pharmaceutical and biotechnology companies with advanced sterile fill and finish services for biologics and advanced therapies.

The investment reflects Recipharm's commitment to expanding US manufacturing capacity, accelerating development timelines and providing customers with seamless access to clinical and commercial manufacturing services. By enhancing its manufacturing infrastructure and technical capabilities, the company is strengthening support across the product lifecycle, from development and scale-up through clinical and commercial supply.

The announcement follows the signing of a clinical biologics fill and finish agreement with a major global pharmaceutical company, demonstrating market demand for high-quality manufacturing solutions and robust US-based capacity for biologics and advanced therapies.

Greg Behar, CEO of Recipharm, said: "The demand for biologics and advanced therapies continues to accelerate, and manufacturers must be ready to meet that challenge with the right capacity, expertise and technology. By expanding our sterile manufacturing capabilities, we are investing in the infrastructure needed to support the next wave of pharmaceutical innovation. This investment enables us to support more programmes from development through commercial supply, while strengthening our ability to help customers scale efficiently and accelerate timelines. The US remains a critical market for our customers, and these investments position Recipharm as a partner of choice for companies bringing the next generation of therapies to patients."